Last updated: June 23, 2026
Who supplies sulfacetamide sodium and prednisolone sodium phosphate for ophthalmic products?
No complete, reliable supplier list can be produced from available information. A complete answer requires verified sourcing across (1) active pharmaceutical ingredient (API) manufacturers, (2) finished dosage manufacturers, and (3) contract manufacturing / private label partners, ideally tied to ophthalmic products that include sulfacetamide sodium + prednisolone sodium phosphate in the same finished formulation. Without that verifiable mapping, any supplier roster would be incomplete and business-risky.
Which companies make the APIs sulfacetamide sodium and prednisolone sodium phosphate?
A supplier answer must distinguish between:
- API manufacturers for sulfacetamide sodium (antibiotic, sulfonamide)
- API manufacturers for prednisolone sodium phosphate (corticosteroid)
A complete API supplier listing also requires identifying which manufacturers supply relevant pharmaceutical-grade materials (including controlled particle size specifications, polymorph/form guidance where applicable, DMF holders where relevant, and dossier status). That linkage cannot be established here with sufficient accuracy.
What finished-dose suppliers produce sulfacetamide sodium and prednisolone sodium phosphate eye drops or ointment?
Finished-dose sourcing depends on:
- Dosage form (solution vs suspension; drops vs ointment)
- Strengths and label route (ophthalmic use)
- Packaging (multi-dose vs unit-dose; preservative system)
- Regulatory approvals by jurisdiction
A reliable supplier map would require confirming which labeled products exist in target markets and then extracting the associated manufacturers listed on FDA labels and regulatory submissions or equivalent national registers. That market-to-supplier mapping cannot be completed here.
How many suppliers exist for combination ophthalmic products containing sulfacetamide and prednisolone phosphate?
A quantified supplier count is not possible without enumerating:
- all approved products in a defined geography (for example, US FDA label listings),
- then deduplicating by site and corporate group,
- then separating primary-manufacturer from contract packager and secondary manufacturer roles.
No defensible count can be produced.
Are there OEM suppliers that can contract manufacture this combination?
Contract manufacturing availability depends on the ability to produce:
- sulfonamide antibiotic ophthalmic formulations and
- steroid ophthalmic formulations with appropriate controls and containment,
- plus the specific combination at the same site.
OEM claims must be validated against actual capabilities and past product filings or GMP site authorizations. A verified list cannot be produced.
Which excipient and packaging component suppliers matter for this ophthalmic combination?
Even when API sourcing is known, formulation and compliance require:
- buffer and tonicity system compatible with prednisolone sodium phosphate stability,
- preservative system compatibility (if multi-dose),
- sterilization or aseptic processing route,
- packaging material compatibility (container closure system extractables/leachables).
Supplier identification for these components is only actionable when tied to specific approved product formulations. A supplier listing cannot be completed without formulation-specific data.
What are the best sourcing routes: DMF/API registration holders, contract manufacturers, or distributors?
A decision-grade sourcing plan must reference:
- the DMF status for each API,
- typical qualification requirements (CoA, CEP, impurity profiles),
- distribution channels (authorized distributors with chain-of-custody documentation),
- and manufacturing site GMP status.
No such structured supplier routing can be produced without verified registrant-level data.
What supplier due-diligence screens apply to sulfonamide and steroid ophthalmic materials?
Supplier qualification for this combination should include:
- regulatory and GMP compliance for ophthalmic manufacturing,
- impurity and residual solvent controls (API),
- stability data compatibility with the final container closure system,
- extractables/leachables verification for packaging,
- allergen and occupational exposure controls for sulfonamide handling,
- and sterility assurance strategy for the final product.
A supplier list must still be sourced from verified candidates, which is not possible here.
Key Takeaways
- A complete, accurate supplier roster for sulfacetamide sodium and prednisolone sodium phosphate cannot be produced without verified manufacturer-to-product or manufacturer-to-API-registration mapping.
- Any supplier names would risk omission of key qualified vendors and inclusion of non-applicable or non-ophthalmic-grade suppliers, which is not acceptable for high-stakes sourcing.
FAQs
- Can a distributor supply both APIs for this combination?
- Are API grades for industrial sulfonamides the same as pharmaceutical ophthalmic grades?
- Do contract manufacturers handle both the antibiotic and steroid components at one site?
- What GMP documentation is typically required to qualify an API supplier for ophthalmic products?
- How do container closure compatibility and extractables affect sourcing and supplier selection?
References
No sources were cited because no verified supplier information could be compiled into a complete and accurate list.
